Why the study?
Does thrombolytic therapy alter platelet expression and plasma concentration of PECAM-1 in patients with acute myocardial infarction?
Population
23 patients with acute myocardial infarction (AMI) enrolled in the GUSTO-III trial, and 22 healthy controls
Comparison
Thrombolytic therapy vs Healthy controls and pre-thrombolysis baseline
Design
Cohort
Follow-up
24 hours
Authors
Loading...
Thrombolysis-linked PECAM-1 shifts in AMI remain hypothesis-generating; leaves open any therapeutic role and should not yet change practice.
Does thrombolytic therapy alter platelet expression and plasma concentration of PECAM-1 in patients with acute myocardial infarction?
Thrombolytic therapy in AMI induces dynamic, discordant changes in soluble and platelet-bound PECAM-1 over 24 hours, suggesting redistribution of the PECAM-1 pool.
Serebruany et al. (1999) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: